Shareholders of Bread Financial Holdings Inc (Symbol: BFH) looking to boost their income beyond the stock's 1.3% annualized dividend yield can sell the November covered call at the $80 strike and collect the premium based on the $6.80 bid, which annualizes to an additional 13% r
Shareholders of Bread Financial Holdings Inc (Symbol: BFH) looking to boost their income beyond the stock's 1.3% annualized dividend yield can sell the November covered call at the $80 strike and collect the premium based on the $6.80 bid, which annualizes to an additional 13% r
In trading on Friday, shares of Biolife Solutions Inc (Symbol: BLFS) crossed above their 200 day moving average of $24.23, changing hands as high as $25.25 per share. Biolife Solutions Inc shares are currently trading up about 11.2% on the day. The chart below shows the one ye
In trading on Friday, shares of Biolife Solutions Inc (Symbol: BLFS) crossed above their 200 day moving average of $24.23, changing hands as high as $25.25 per share. Biolife Solutions Inc shares are currently trading up about 11.2% on the day. The chart below shows the one ye
In trading on Friday, shares of NBT Bancorp. Inc. (Symbol: NBTB) crossed below their 200 day moving average of $42.58, changing hands as low as $42.28 per share. NBT Bancorp. Inc. shares are currently trading down about 4.3% on the day. The chart below shows the one year perfo
In trading on Friday, shares of NBT Bancorp. Inc. (Symbol: NBTB) crossed below their 200 day moving average of $42.58, changing hands as low as $42.28 per share. NBT Bancorp. Inc. shares are currently trading down about 4.3% on the day. The chart below shows the one year perfo
Shareholders of Installed Building Products Inc (Symbol: IBP) looking to boost their income beyond the stock's 0.5% annualized dividend yield can sell the September covered call at the $390 strike and collect the premium based on the $23.00 bid, which annualizes to an additional
Shareholders of Installed Building Products Inc (Symbol: IBP) looking to boost their income beyond the stock's 0.5% annualized dividend yield can sell the September covered call at the $390 strike and collect the premium based on the $23.00 bid, which annualizes to an additional
In trading on Friday, shares of SiriusXM Holdings Inc (Symbol: SIRI) crossed above their 200 day moving average of $22.01, changing hands as high as $22.16 per share. SiriusXM Holdings Inc shares are currently trading up about 2.5% on the day. The chart below shows the one yea
In trading on Friday, shares of SiriusXM Holdings Inc (Symbol: SIRI) crossed above their 200 day moving average of $22.01, changing hands as high as $22.16 per share. SiriusXM Holdings Inc shares are currently trading up about 2.5% on the day. The chart below shows the one yea
The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks, according to a proprietary formula designed to identify those stocks that combine two important characteristics — strong fundamentals and a valuation that looks inexpensive.
The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks, according to a proprietary formula designed to identify those stocks that combine two important characteristics — strong fundamentals and a valuation that looks inexpensive.
In trading on Friday, shares of Diversified Energy Company (Symbol: DEC) crossed above their 200 day moving average of $14.23, changing hands as high as $14.42 per share. Diversified Energy Company shares are currently trading up about 11.1% on the day. The chart below shows t
In trading on Friday, shares of Diversified Energy Company (Symbol: DEC) crossed above their 200 day moving average of $14.23, changing hands as high as $14.42 per share. Diversified Energy Company shares are currently trading up about 11.1% on the day. The chart below shows t
The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks, according to a proprietary formula designed to identify those stocks that combine two important characteristics — strong fundamentals and a valuation that looks inexpensive.
The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks, according to a proprietary formula designed to identify those stocks that combine two important characteristics — strong fundamentals and a valuation that looks inexpensive.
The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks, according to a proprietary formula designed to identify those stocks that combine two important characteristics — strong fundamentals and a valuation that looks inexpensive.
The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks, according to a proprietary formula designed to identify those stocks that combine two important characteristics — strong fundamentals and a valuation that looks inexpensive.
Earnings Call Insights: Caris Life Sciences (CAI) Q4 2025 Management View Brian Brille, Executive Vice Chairman & Executive VP, highlighted Caris' record-breaking quarter, with total revenues increasing 125% year-over-year to $293 million, driven by strong clinical profiling, and noted "Molecular profiling services revenues increased to $282 million in the fourth quarter representing an increase o...
Earnings Call Insights: Caris Life Sciences (CAI) Q4 2025 Management View Brian Brille, Executive Vice Chairman & Executive VP, highlighted Caris' record-breaking quarter, with total revenues increasing 125% year-over-year to $293 million, driven by strong clinical profiling, and noted "Molecular profiling services revenues increased to $282 million in the fourth quarter representing an increase of 199% year-over-year." Brille emphasized the achievement of positive GAAP net income of $82 million, adjusted EBITDA of $106 million, and free cash flow of $39.7 million, stating "This is our third straight quarter of positive adjusted EBITDA and positive free cash flow. This strong profitability profile is unique in our industry and provides valuable strategic flexibility for ongoing investment." The company achieved a significant milestone with its molecular data set now exceeding 1 million profiled cases, enhancing its position as a key clinical genomic resource. Brille announced the launch plans for Caris Detect, a new cancer early detection test, in 2026: "Caris Detect has the potential to bend the cancer mortality curve and ultimately make cancer a curable disease." A new Chief Commercial Officer, Bobby Hill, was appointed in the fourth quarter to drive commercial expansion and sales force growth. Hill stated, "Our Q4 growth was 20%, which was sequential improvement from 18% in Q3 '25, with Caris Assure delivering 59% year-over-year growth in Q4 '25 and continuing to gain traction." President David Spetzler presented interim results for the ACHIEVE-1 study, supporting the upcoming launch of Caris Detect, reporting "Stage I and II combined, ACHIEVE-1 reported 63.1% sensitivity… specificity in the screening population…99.1%." CFO Luke Power explained the strategic approach to investments: "For the full year of 2026, we expect total revenue for existing solutions to be in the range of $1.0 billion to $1.02 billion, which represents growth of approximately 23% to 26% com...
Lars Neumann Merck ( MRK ) said that an analysis of a phase 3 trial found that treatment with Keytruda (pembrolizumab) led to a significant improvement in overall survival regardless of an ovarian cancer patient's PD-L1 status. The pharma also noted that the results were seen with or without Avastin (bevacizumab). With a median follow-up of 32.7 months. Keytruda plus paclitaxel with or without Ava...
Lars Neumann Merck ( MRK ) said that an analysis of a phase 3 trial found that treatment with Keytruda (pembrolizumab) led to a significant improvement in overall survival regardless of an ovarian cancer patient's PD-L1 status. The pharma also noted that the results were seen with or without Avastin (bevacizumab). With a median follow-up of 32.7 months. Keytruda plus paclitaxel with or without Avastin reduced the risk of death by 18% compared to paclitaxel with or without Avastin alone. For those on Keytruda, median OS was 17.7 months compared to 14 months for those taking the placebo regimen. Merck had previously released data showing that the Keytruda regimen met its primary endpoint, progression-free survival. Overall survival was the secondary endpoint in the KEYNOTE-B96 trial. The European Medicines Agency’s Committee for Medicinal Products also adopted a positive opinion for approving the Keytruda regimen for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma in adults whose tumors express PD-L1 and who have received at least one or two prior treatments. The US FDA granted that indication for Keytruda earlier in February. Merck also released data on Keytruda plus Pfizer ( PFE ) and Astellas' ( ALPMF )( ALPMY ) antibody-drug conjugate Padcev (enfortumab vedotin) for muscle-invasive bladder cancer. Results showed the combination reduced the risk of event-free survival events by 47% and cut the risk of death by 35% when given before and after surgery versus neoadjuvant chemotherapy and surgery. More on Merck Health Care Q4 Dividend Roundup: Merck Offers Thicker Dividend Cushion Than AbbVie Merck: Why Investors Should Remain Bullish Despite Patent Risks Merck: Keytruda Remains Resilient Despite LOE Risks - Buy Upon Correction FDA reportedly eyeing staff bonuses to accelerate drug reviews 15 states sue Trump administration over changes to U.S. vaccine schedule
Ginkgo Bioworks Holdings ( DNA ): Q4 Revenue of $33M (-24.7% Y/Y) misses by $4.57M . Fourth quarter 2025 Cell Engineering revenue of $26 million compared to $35 million in the comparable prior year period, a decrease of 26% Fourth quarter 2025 Biosecurity revenue of $7 million compared to $9 million in the comparable prior year period Fourth quarter 2025 GAAP net loss of $(81) million, compared to...
Ginkgo Bioworks Holdings ( DNA ): Q4 Revenue of $33M (-24.7% Y/Y) misses by $4.57M . Fourth quarter 2025 Cell Engineering revenue of $26 million compared to $35 million in the comparable prior year period, a decrease of 26% Fourth quarter 2025 Biosecurity revenue of $7 million compared to $9 million in the comparable prior year period Fourth quarter 2025 GAAP net loss of $(81) million, compared to $(108) million in the comparable prior year period Fourth quarter 2025 Adjusted EBITDA of $(36) million, up from $(57) million in the comparable prior year period, primarily attributable to the decrease in operating expenses in the prior year period Cash, cash equivalents and marketable securities balance as of December 31, 2025 of $423 million More on Ginkgo Bioworks Holdings Ginkgo Bioworks Holdings, Inc. (DNA) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow Ginkgo Bioworks Holdings, Inc. (DNA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Ginkgo - OpenAI collaboration cuts costs in protein synthesis Seeking Alpha’s Quant Rating on Ginkgo Bioworks Holdings Historical earnings data for Ginkgo Bioworks Holdings
OpenAI (Unlisted:OPAI) has announced a $110 billion funding round, pushing the company’s pre-money valuation to $730 billion, up from $500 billion in a secondary financing last October. The round includes $50 billion from Amazon.com Inc (NASDAQ:AMZN), $30 billion from Nvidia Corp...
OpenAI (Unlisted:OPAI) has announced a $110 billion funding round, pushing the company’s pre-money valuation to $730 billion, up from $500 billion in a secondary financing last October. The round includes $50 billion from Amazon.com Inc (NASDAQ:AMZN), $30 billion from Nvidia Corp...
Software is rapidly reducing operating expenses for businesses. In the past, the undeniable tailwinds fueling SaaS companies led to lofty valuation multiples that made it easier to raise capital. But this was a double-edged sword as the high prices exposed them to big drawdowns, and unfortunately, the industry has tumbled by 23.6% over the last six months. This drop is a noticeable divergence from...
Software is rapidly reducing operating expenses for businesses. In the past, the undeniable tailwinds fueling SaaS companies led to lofty valuation multiples that made it easier to raise capital. But this was a double-edged sword as the high prices exposed them to big drawdowns, and unfortunately, the industry has tumbled by 23.6% over the last six months. This drop is a noticeable divergence from the S&P 500’s 7.2% return.